Sanofi (SNY) said Wednesday it has opened the Charles Best Building flu vaccine manufacturing facility within the Sanofi Toronto campus that will manufacture its Fluzone High-Dose influenza vaccine.

The expansion, which is worth 925 million Canadian dollars ($663.7 million), comprises CA$415 million in partnership from the Government of Canada and CA$55 million from the Government of Ontario.

The company said the facility is now fully operational and will start production early next year, pending regulatory approval.

Price: 42.89, Change: +0.49, Percent Change: +1.16